Holen Sie sich die Stockscreener-App
44.61
4.79%
2.04
Vorhandelsmarkt:
44.71
0.10
+0.22%
Terns Pharmaceuticals Inc Aktie (TERN) Neueste Nachrichten
Terns Pharmaceuticals Stock Surge: Analyzing the Leap - StocksToTrade
Terns Pharmaceuticals Stock Soars After Leukemia Drug Delivers Big Early Responses In Tough-To-Treat Patients - Stocktwits
Jefferies raises Terns Pharmaceuticals stock price target to $70 on CML data - Investing.com
Terns Pharmaceuticals Stock Soars Amid Promising Drug Trial - TipRanks
Terns Pharmaceutical prices stock at $40 per share - MSN
TERN Upsizes Stock Offering to $502M - GuruFocus
Terns Pharmaceuticals (TERN) Announces Upsized Public Offering - GuruFocus
Why Terns Pharmaceuticals (TERN) Is Up 54.9% After Upsized $650 Million Equity Raise Following TERN-701 Data - Yahoo Finance
Terns Pharmaceuticals proposes $400M equity offering - MSN
Terns Pharmaceuticals Prices Upsized $650 Million Common Stock Offering - marketscreener.com
Terns Pharmaceuticals (TERN): Reassessing Valuation After CARDINAL CML Data Fuels Sharp Share Price Surge - Yahoo Finance
Terns Pharmaceuticals prices upsized $650 million public offering By Investing.com - Investing.com South Africa
Terns Pharmaceuticals prices upsized $650 million public offering - Investing.com
Terns Announces Pricing of Upsized $650 Million Public Offering - The Manila Times
Terns Announces Pricing of Upsized $650 Million Public Offering | Associated Press | syndication news - Enidnews.com
Terns Pharmaceuticals Stock Skyrockets: Should You Dive In? - StocksToTrade
Terns (TERN) Hits All-Time High on Stellar Leukemia Treatment Results - Finviz
Terns Pharmaceuticals: CML Data Blows Wall Street AwayAgain (NASDAQ:TERN) - Seeking Alpha
Oppenheimer Raises TERN Price Target by 107% to $58 | TERN Stock News - GuruFocus
Terns Pharma (TERN) Analyst Rating Update: Price Target Raised b - GuruFocus
Barclays Raises Terns Pharma (TERN) Price Target to $56 | TERN Stock News - GuruFocus
Terns Pharmaceuticals price target raised to $56 from $35 at Truist - TipRanks
Terns Pharmaceuticals stock rating reiterated by BMO Capital with $54 target - Investing.com South Africa
Terns Pharmaceuticals (TERN) Announces $400M Public Offering Pla - GuruFocus
Mizuho Raises Terns Pharma (TERN) Price Target to $54, Maintains Outperform Rating | TERN Stock News - GuruFocus
Oppenheimer Adjusts PT on Terns Pharmaceuticals to $58 From $28, Maintains Outperform Rating - marketscreener.com
Broadcom To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Terns Pharmaceuticals price target raised to $58 from $28 at Oppenheimer - TipRanks
Terns Pharmaceuticals (TERN) Launches $400M Public Offering - GuruFocus
Terns Pharmaceuticals price target raised to $54 from $33 at Mizuho - TipRanks
Truist Raises Price Target on Terns Pharmaceuticals to $56 From $35, Keeps Buy Rating - marketscreener.com
Mizuho Raises Price Target on Terns Pharmaceuticals to $54 From $33, Keeps Outperform Rating - marketscreener.com
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster - Benzinga
Terns Pharmaceuticals launches $400 million public offering By Investing.com - Investing.com Nigeria
H.C. Wainwright raises Terns Pharmaceuticals stock price target to $60 on CML drug data - Investing.com UK
Mizuho raises Terns Pharmaceuticals stock price target to $54 on CML drug data - Investing.com
HC Wainwright & Co. Maintains Terns Pharmaceuticals (TERN) Buy Recommendation - Nasdaq
Terns Pharmaceuticals (TERN) Launches $400M Public Stock Offerin - GuruFocus
Terns Pharmaceuticals Launches $400 Million Public Offering - Nasdaq
Terns Announces Proposed Public Offering - The Manila Times
Terns announces proposed public offering - marketscreener.com
Terns Pharmaceuticals (Nasdaq: TERN) starts $400M stock offering with $60M option - Stock Titan
Terns Pharmaceuticals (TERN): Evaluating Rich Valuation After CARDINAL Trial Update and 2025 ASH Presentation - simplywall.st
10 Stocks Standing Tall Amid Market Fall; 6 Hit Record Highs - Insider Monkey
Terns CEO says 'delighted' by 'unprecedented' Phase 1 data for TERN-701 - MSN
Oppenheimer raises Terns Pharmaceuticals stock price target to $58 on CML drug data - Investing.com Canada
Terns Pharmaceuticals’ Path: A Stock to Watch? - timothysykes.com
Terns Pharmaceuticals Unveils Promising Phase 1 Trial Data - TipRanks
Terns Pharmaceuticals Presents Positive Phase 1 Data for TERN-701 in CML - TradingView
Terns Pharmaceuticals says safety profile maintained with longer treatment duration - marketscreener.com
Terns’ leukemia drug shows 64% response rate in phase 1 trial - Investing.com
Terns Pharmaceuticals (TERN) Unveils Promising Data from CARDINA - GuruFocus
Terns Pharmaceuticals stock soars after positive Phase 1 CML drug data By Investing.com - Investing.com South Africa
Terns Pharmaceuticals stock soars after positive Phase 1 CML drug data - Investing.com UK
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):